Disclosures for "Cerebral Vasculitis in a patient receiving Risankizumab, an Inhibitor of Interleukin-23: First Case Report")
-
Dr. Cabrera Pulla has nothing to disclose.
-
Dr. Amirjanyan has nothing to disclose.
-
Qian Wu has nothing to disclose.
-
Dr. Mui has nothing to disclose.
-
Dr. Imitola has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis . The institution of Dr. Imitola has received research support from biogen. Dr. Imitola has a non-compensated relationship as a Board Member with National MS Society that is relevant to AAN interests or activities. Dr. Imitola has a non-compensated relationship as a Committee Member with International Society for Stem Cell Research that is relevant to AAN interests or activities.
-
Dr. Coban has nothing to disclose.